Stay updated on AK104 in NSCLC Phase II Clinical Trial

Sign up to get notified when there's something new on the AK104 in NSCLC Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AK104 in NSCLC Phase II Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The website’s footer revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-01T23:22:31.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A new NIH-wide banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    0.8%
    Check dated 2026-10-25T22:42:15.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T22:48:25.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T23:08:40.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the study record history, and the previous revision v3.6.6 was removed. This updates the page's version history to reflect the latest revision.
    Difference
    0.1%
    Check dated 2026-09-20T20:34:59.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The study record history now displays a new revision tag v3.6.6, replacing the previous v3.6.5. This confirms an update to the page's revision history for the record.
    Difference
    0.1%
    Check dated 2026-08-30T22:00:29.000Z thumbnail image

Stay in the know with updates to AK104 in NSCLC Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AK104 in NSCLC Phase II Clinical Trial page.